$TNDM

Tandem Diabetes ($TNDM) 10x play or getting bought out privately in the next few years ($825k bet)

Tandem Diabetes is transitioning to a SaaS-like PayGo model that doubles recurring revenue per patient while improving margins and cash flow trajectory toward 2027 positivity. The company earns its current market cap in annual revenue with limited competition, making it a compelling M&A target for PE/strategic buyers or a multi-bagger if it executes independently.